Brief: Evofem Expects Significant Reduction In PHEXXI Manufacturing Cost Through Agreement With Windtree Therapeutics
26/03/2025 12:49
March 26 (Reuters) - Evofem Biosciences Inc EVFM.PK: EVOFEM EXPECTS SIGNIFICANT REDUCTION IN PHEXXI MANUFACTURING COST THROUGH AGREEMENT WITH WINDTREE THERAPEUTICS EVOFEM BIOSCIENCES INC - COST TO MANUFACTURE PHEXXI WILL DECREASE BY 55% - 60% Source text: ID:nPnbPdj8Da Further company coverage: EVFM.PK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Windtree Therapeutics
See all newsBrief: Windtree Therapeutics Announces It Has Signed A Letter Of Intent To Acquire Commloan
Brief: Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Brief: Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Brief: Windtree Therapeutics Terminates Seismic-C Clinical Study At 20 Enrollments - SEC Filing
Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study